ベースラインMRIとCRPで層別化したX線基準を満たさない体軸性脊椎関節炎におけるセルトリズマブペゴルの有効性: C-axSpAnd 試験結果
ACR Open Rheumatol. 2022 doi: 10.1002/acr2.11469
The results of this analysis indicated that certolizumab pegol (CZP) treatment benefits patients with nr-axSpA across all the MRI/CRP subgroups studied. To reach this conclusion, this study evaluated clinical responses to CZP in patients with nr-axSpA stratified by baseline MRI/CRP status.